TOKYO -- Domestic COVID drugs are arriving in Japan and South Korea, providing more treatment options for doctors fighting against the omicron wave of COVID cases.
On Jan. 21, Japan approved Chugai Pharmaceutical's Actemra arthritis drug for treatment of severe COVID symptoms. Actemra helps reduce inflammation in COVID patients by blocking interleukin-6, a protein that activates the immune system. The Japanese drug has already been approved as a COVID treatment in the U.S. and Europe.
